A recent RCT reveals the HEAL ABC intervention is feasible for 87% of colorectal cancer survivors, supporting healthy lifestyle changes and improved well-being.
PRODIGY BIOTECH ENTERS INTO A PARTNERSHIP AGREEMENT WITH LEADING CANCER CENTER TO ADVANCE PRODUCTS TO IMPROVE OUTCOMES IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION – Biotech Investments
ProdIgy Biotech PRODIGY BIOTECH ENTERS INTO A PARTNERSHIP AGREEMENT WITH LEADING CANCER CENTER TO ADVANCE PRODUCTS TO IMPROVE OUTCOMES IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM